2024 Prediction from Robert E. White Jr.
Robert E. White Jr. is the President of The Doctors Company. He believes "social inflation will affect malpractice insurers."
We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Robert E. White Jr. had to say:
“Social inflation occurs when an insurer’s average claim amount grows faster than the overall inflation rate. Over the decade ending in 2021, social inflation has led to losses estimated to be between $2.4 billion and $3.5 billion — 8% to 11% — of all medical malpractice losses incurred by physician- focused insurers. The rapid uptick began in 2019. People are sympathetic to injured patients. Jurors also relate to credible, empathetic medical professionals, but it can be harder to evoke sympathy for a hospital.
As these cost trends continue, medical professional liability carriers may have to increase their rates to keep up with the losses. Therefore, although social inflation hits insurers first, it affects practices’ premiums.”
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 13th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
